Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Gynecol Oncol. 2021 Nov;163(2):305-311. doi: 10.1016/j.ygyno.2021.08.015. Epub 2021 Aug 26.
During 2000-2014, age-standardized five-year net survival for cervical cancer was 63-64% in the United States. Using data from CONCORD-3, we analyzed cervical cancer survival trends by race, stage and period of diagnosis.
Data from 41 state-wide population-based cancer registries on 138,883 women diagnosed with cervical cancer during 2001-2014 were available. Vital status was followed up until December 31, 2014. We estimated age-standardized five-year net survival, by race (Black or White), stage and calendar period of diagnosis (2001-2003, 2004-2008, 2009-2014) in each state, and for all participating states combined.
White women were most commonly diagnosed with localized tumors (45-50%). However, for Black women, localized tumors were the most common stage (43.0%) only during 2001-2003. A smaller proportion of Black women received cancer-directed surgery than White women. For all stages combined, five-year survival decreased between 2001-2003 and 2009-2014 for both White (64.7% to 63.0%) and Black (56.7% to 55.8%) women. For localized and regional tumors, survival increased over the same period for both White (by 2-3%) and Black women (by 5%). Survival did not change for Black women diagnosed with distant tumors but increased by around 2% for White women.
Despite similar screening coverage for both Black and White women and improvements in stage-specific survival, Black women still have poorer survival than White women. This may be partially explained by inequities in access to optimal treatment. The results from this study highlight the continuing need to address the disparity in cervical cancer survival between White and Black women in the United States.
在 2000 年至 2014 年期间,美国宫颈癌的五年标准化净生存率为 63-64%。本研究利用 CONCORD-3 的数据,分析了种族、分期和诊断时期对宫颈癌生存趋势的影响。
本研究纳入了来自 41 个州立人群癌症登记处的 138883 名宫颈癌确诊患者的数据,诊断时间为 2001 年至 2014 年。截至 2014 年 12 月 31 日,对所有患者的生存状态进行随访。本研究在每个州和所有参与州中,按种族(黑人或白人)、分期(局部、区域、远处)和诊断时间(2001-2003、2004-2008、2009-2014)对五年标准化净生存率进行了估计。
白人患者最常被诊断为局限性肿瘤(45-50%)。然而,仅在 2001-2003 年,黑人患者的局限性肿瘤最常见(43.0%)。与白人患者相比,黑人患者接受癌症定向手术的比例较小。对于所有分期,白人(从 64.7%降至 63.0%)和黑人(从 56.7%降至 55.8%)患者的五年生存率均在 2001-2003 年至 2009-2014 年期间下降。对于局限性和区域性肿瘤,同期白人(增加 2-3%)和黑人(增加 5%)患者的生存率均升高。远处肿瘤患者的生存率没有变化,但白人患者的生存率提高了约 2%。
尽管黑人和白人女性的筛查覆盖率相似,且各分期特异性生存率有所提高,但黑人女性的生存率仍低于白人女性。这可能部分归因于接受最佳治疗的机会不平等。本研究结果强调了继续解决美国白人和黑人女性宫颈癌生存差异的必要性。